Profile: Checkpoint Therapeutics Inc (CKPT.OQ)
17 Jan 2018
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). The Company focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. The Company is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). The Company is developing a clinical program for its PARP inhibitor. Additionally, it seeks to add additional immuno-oncology drugs, as well as other targeted therapies to create wholly-owned combinations that leverage the immune system and other complimentary mechanisms.
The Company's pipeline of products includes Anti- carbonic anhydrase IX (CAIX), anti-GITR monoclonal antibody (mAb), anti-PD-L1 mAb, CK-101, CK-102 PARP and CK-103. Anti-CAIX is a human pre-clinical antibody designed to recognize CAIX expressing cells and kill them through antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). CAIX is a tumor associated antigen (TAA). It is in the preclinical development for Anti-CAIX. Its anti-GITR mAb is a human agonistic antibody that binds and triggers signaling in GITR expressing cells. GITR is a co-stimulatory molecule of the TNFR family and is expressed on activated T cells, B cells, natural killer (NK) and regulatory T cells (Treg). The Company focuses on developing an anti-GITR antibody for oncology indications, including the treatment of patients with non-small cell lung cancer (NSCLC) and regional cancer center (RCC). It is in the preclinical development for anti-GITR.
The Company's anti-PD-L1 mAb is a human antagonistic antibody that binds PD-L1 and blocks its interaction with Programmed cell death protein 1 (PD-1). PD-1 and its ligand PD-L1 are checkpoints of immune activation and is engaged in the negative regulation of T-cell effector function and proliferation. Its CK-101 is an oral, third generation covalent inhibitor against selective mutations of EGFR. The EGFR T790M gatekeeper mutation is a resistant mutation found in patients treated with first generation EGFR inhibitors. The mutation decreases the affinity of first generation inhibitors to EGFR kinase domain. It focuses on initiating a Phase I/II clinical study. The Company focuses on developing and commercializing CK-102, which is oral, small molecule selective inhibitor of PARP-1 and PARP-2 enzymes in early clinical development for solid tumors. It focuses on commence a Phase 1b clinical study. The Company is developing CK-103, an oral, inhibitor of the BET protein, BRD4. A bromodomain is an amino acid protein domain that recognizes acetylated-lysine. The binding of the drug prevents interaction between BET proteins, and both acetylated histones and transcription factors.
Checkpoint Therapeutics Inc
2 Gansevoort St Fl 9
NEW YORK NY 10014-1667